Drugs / RAG-18
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 0 | NCT07282652 | Dec 2025 → Nov 2026 expected | Duchenne muscular dystrophy | Peking Union Medical College Hospital | Active not recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 3
| Date | Issuer | Release |
|---|---|---|
| 2024-08-22 | Ractigen Therapeutics. | Regulatory Ractigen Therapeutics Announces U.S. FDA Orphan Drug Designation (ODD) granted to RAG-18 for the treatment of Duchenne Muscular Dystrophy and Becker Muscular Dystrophy ractigen.com ↗
Ractigen Therapeutics, a pioneering developer of small activating RNA (saRNA) therapeutics, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to RAG-18, one of the company’s lead saRNA product candidates. |
| 2024-07-25 | Ractigen Therapeutics. | Regulatory Ractigen Announces U.S. FDA Rare Pediatric Disease Designation (RPDD) Granted to RAG-18 for the treatment of Duchenne Muscular Dystrophy ractigen.com ↗
Ractigen Therapeutics, a pioneering developer of small activating RNA (saRNA) therapeutics, today announced that the U.S. Food and Drug Administration (FDA) has granted Rare Pediatric Disease Designation (RPDD) to RAG-18, one of the company’s lead saRNA product candidates for the treatment of Duchenne Muscular Dystrophy (DMD). |
| 2023-11-02 | Ractigen Therapeutics. | Results Ractigen Presents Preclinical Results of Its saRNA Therapeutic Targeting DMD/BMD at the Oligonucleotide Therapeutics Society (OTS) Annual Meeting ractigen.com ↗
In a proof-of-concept efficacy study in MDX mice bearing the human UTRN promotor, systemic administration of a lead saRNA conjugated to Ractigen’s proprietary LiCO TM delivery system ameliorated muscle damage. |
All press releases naming this drug 5 releases
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | RAG-18 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07282652 ↗ |
| Modality | Small activating RNA (saRNA) | “small activating RNA (saRNA)” NCT07282652 ↗ |
| Route | Intravenous | “ascending intravenous doses” NCT07282652 ↗ |